Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists
Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists
复制标题
DOI：
10.1377/hlthaff.2009.0077
复制
发表时间：
2010-01-01
期刊：
影响因子：
9.7
通讯作者：
Ubel, Peter
中科院分区：
文献类型：
--
作者：
Neumann, Peter J.;Palmer, Jennifer A.;Ubel, Peter
一项对医学肿瘤学家的全国性调查表明，癌症治疗成本的上升正在影响临床实践，尽管肿瘤学家往往不会与患者就成本进行沟通。调查显示，84%的肿瘤学家表示，患者的自掏腰包支出会影响治疗建议。只有43%的人总是或经常与患者讨论费用。在接受调查的人中，79%的人支持更多的比较有效性研究；80%的人支持更多的成本效益数据，尽管只有42%的人觉得准备好了解读它。结果表明，医生支持联邦资助的比较有效性研究，但他们希望在决定如何以及何时使用昂贵的癌症治疗方面保持核心作用。研究结果还支持对医生进行有关成本效益的教育，以及如何与患者就成本进行沟通。
A national survey of medical oncologists indicates that rising cancer treatment costs are influencing clinical practice, even as oncologists tend not to communicate with patients about costs. The survey shows that 84 percent of oncologists say that patients' out-of-pocket spending influences treatment recommendations. Only 43 percent always or frequently discuss costs with patients. Among those surveyed, 79 percent favor more comparative effectiveness research; 80 percent support more cost-effectiveness data, although only 42 percent feel well prepared to interpret it. The results suggest that physicians support federally funded comparative effectiveness research but that they wish to retain a central role in making decisions about how and when to use expensive cancer treatments. The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost.